1. 1 Sebban C, Mounier N, Brousse N, Belanger C, Brice P, et al.: Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108:2540-2544, 2006
2. 2 Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, et al.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
3. 3 Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, et al.: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
4. 4 Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, et al.: Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122:981-987, 2013
5. 5 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005